iBio reports new preclinical data on obesity candidate IBIO-610 and amylin programNov 16Clinical readoutiBio, Inc.
iBio reports fiscal Q1 2027 results, advances IBIO-600 and IBIO-610 programsNov 10Clinical readoutiBio, Inc.PMGC Holdings Inc.Updated
iBio highlights NHP data showing IBIO-610 may preserve muscle with GLP-1 therapyOct 13Clinical readoutiBio, Inc.
iBio reports fiscal 2026 results, cites progress across obesity antibody pipelineAug 28Quarterly updateiBio, Inc.